{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:13:41Z","timestamp":1789020821524,"version":"build-2803163510"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>As one of the most severe forms of muscle dystrophy, Duchenne muscular dystrophy (DMD) results in progressive muscle wasting, ultimately resulting in premature death due to cardiomyopathy. In the many years of research, the solution to DMD remains palliative. Although numerous studies including clinical trials have provided promising results, approved drugs, even, the therapeutic window is still minimal with many shortcomings to be addressed. Logically, to combat DMD that arose from a single genetic mutation with gene therapy made sense. However, gene-based strategies as a treatment option are no stranger to drawbacks and limitations such as the size of the dystrophin gene and possibilities of vectors to elicit immune responses. In this systematic review, we aim to provide a comprehensive compilation on gene-based therapeutic strategies and critically evaluate the approaches relative to its efficacy and feasibility while addressing their current limitations. With the keywords \u201cDMD AND Gene OR Genetic AND Therapy OR Treatment,\u201d we reviewed papers published in Science Direct, PubMed, and ProQuest over the past decade (2012\u20132021).<\/jats:p>","DOI":"10.3389\/fbioe.2022.833833","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T17:38:37Z","timestamp":1655487517000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Lam","family":"Chung Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiah","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Dain","family":"Yazid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","article-title":"The Importance of Genetic Diagnosis for Duchenne Muscular Dystrophy","volume":"53","author":"Aartsma-Rus","year":"2016","journal-title":"J. Med. Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3390\/jcm9103186","article-title":"Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies","volume":"9","author":"Adorisio","year":"2020","journal-title":"Jcm"},{"key":"B3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41434-020-0146-8","article-title":"Muscle Overexpression of Klf15 via an AAV8-Spc5-12 Construct Does Not Provide Benefits in Spinal Muscular Atrophy Mice","volume":"27","author":"Ahlskog","year":"2020","journal-title":"Gene Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4097\/kjae.2018.71.2.103","article-title":"Introduction to Systematic Review and Meta-Analysis","volume":"71","author":"Ahn","year":"2018","journal-title":"Korean J. Anesthesiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.omtn.2018.10.002","article-title":"Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD","volume":"13","author":"Akpulat","year":"2018","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/jcph.1015","article-title":"Application of Quantitative Pharmacology Approaches in Bridging Pharmacokinetics and Pharmacodynamics of Domagrozumab from Adult Healthy Subjects to Pediatric Patients with Duchenne Muscular Disease","volume":"58","author":"Bhattacharya","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1172\/jci142031","article-title":"Stem Cell Therapy for Muscular Dystrophies","volume":"130","author":"Biressi","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0198897","DOI":"10.1371\/journal.pone.0198897","article-title":"Peptide-conjugated Phosphodiamidate Oligomer-Mediated Exon Skipping Has Benefits for Cardiac Function in Mdx and Cmah-\/-Mdx Mouse Models of Duchenne Muscular Dystrophy","volume":"13","author":"Blain","year":"2018","journal-title":"PLoS ONE"},{"key":"B85","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yjmcc.2012.05.002","article-title":"AAV Micro-Dystrophin Gene Therapy Alleviates Stress-Induced Cardiac Death But Not Myocardial Fibrosis in >21-m-Old Mdx Mice, An End -Stage Model of Duchenne Muscular Dystrophy Cardiomyopathy","volume":"53","author":"Bostick","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-13-73","article-title":"Genetic Characterization in Symptomatic Female DMD Carriers: Lack of Relationship Between X-Inactivation, Transcriptional DMD Allele Balancing and Phenotype","volume":"13","author":"Brioschi","year":"2012","journal-title":"BMC Med. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1172\/JCI136873","article-title":"Correction of Muscular Dystrophies by CRISPR Gene Editing","volume":"130","author":"Chemello","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature24268","article-title":"Enhanced Proofreading Governs CRISPR-Cas9 Targeting Accuracy","volume":"550","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1083\/jcb.151.6.1321","article-title":"Expression Profiling in the Muscular Dystrophies","volume":"151","author":"Chen","year":"2000","journal-title":"J. Cel Biol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis Eliminates the Negatives Impacts of AAV Antibodies on Microdystrophin Gene Expression Following Vascular Delivery","volume":"22","author":"Chicoine","year":"","journal-title":"Mol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/mt.2013.246","article-title":"Vascular Delivery of rAAVrh74.MCK.GALGT2 to the Gastrocnemius Muscle of the Rhesus Macaque Stimulates the Expression of Dystrophin and Laminin \u03b12 Surrogates","volume":"22","author":"Chicoine","year":"","journal-title":"Mol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular Mechanisms of Antisense Oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/dnnd.s170087","article-title":"Efficacy of Stem Cell Therapy in Ambulatory and Nonambulatory Children with Duchenne Muscular Dystrophy \u2013 Phase I\u2013II","volume":"8","author":"Dai","year":"2018","journal-title":"Dnnd"},{"key":"B16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","article-title":"CRISPR-induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo","volume":"26","author":"Duch\u00eane","year":"2018","journal-title":"Mol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene Therapy Comes of Age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy","volume":"25","author":"Echigoya","year":"2017","journal-title":"Mol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne Muscular Dystrophy: From Diagnosis to Therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules"},{"key":"B22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ana.24365","article-title":"Clinical Phenotypes as Predictors of the Outcome of Skipping aroundDMDexon 45","volume":"77","author":"Findlay","year":"2015","journal-title":"Ann. Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The Dystrophin Complex: Structure, Function, and Implications for Therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular Nanovesicles for Packaging of CRISPR-Cas9 Protein and sgRNA to Induce Therapeutic Exon Skipping","volume":"11","author":"Gee","year":"2020","journal-title":"Nat. Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.01135","article-title":"Isolating Human Monoclonal Antibodies against Adeno-Associated Virus from Donors with Pre-existing Immunity","volume":"11","author":"Giles","year":"2020","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jns.2013.09.036","article-title":"Symptomatic Female Carriers of Duchenne Muscular Dystrophy (DMD): Genetic and Clinical Characterization","volume":"336","author":"Giliberto","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e3015","DOI":"10.1002\/jgm.3015","article-title":"Gene Therapy Clinical Trials Worldwide to 2017: An Update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/mgg3.144","article-title":"Pseudoexon Activation Increases Phenotype Severity in a becker Muscular Dystrophy Patient","volume":"3","author":"Greer","year":"2015","journal-title":"Mol. Genet. Genomic Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008.Developing","article-title":"Developing Standardized Corticosteroid Treatment for Duchenne Muscular Dystrophy","volume":"58","author":"Guglieri","year":"2017","journal-title":"Contemp. Clin. Trials"},{"key":"B30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","article-title":"Pharmacological Advances for Treatment in Duchenne Muscular Dystrophy","volume":"34","author":"Guiraud","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00109-020-01893-z","article-title":"Mitigating Off-Target Effects in CRISPR\/Cas9-mediated In Vivo Gene Editing","volume":"98","author":"Han","year":"2020","journal-title":"J. Mol. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/mt.2015.5","article-title":"Intra-Amniotic rAAV-Mediated Microdystrophin Gene Transfer Improves Canine X-Linked Muscular Dystrophy and May Induce Immune Tolerance","volume":"23","author":"Hayashita-Kinoh","year":"2015","journal-title":"Mol. Therapy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/ca.23042","article-title":"Systematic Reviews versus Narrative Reviews in Clinical Anatomy: Methodological Approaches in the Era of Evidence\u2010based Anatomy","volume":"31","author":"Henry","year":"2018","journal-title":"Clin. Anat."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1111\/febs.15466","article-title":"The Discovery of Dystrophin, the Protein Product of the Duchenne Muscular Dystrophy Gene","volume":"287","author":"Hoffman","year":"2020","journal-title":"Febs J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"101562","DOI":"10.1016\/j.scr.2019.101562","article-title":"Generation of Two Duchenne Muscular Dystrophy Patient-specific Induced Pluripotent Stem Cell Lines DMD02 and DMD03 (MUNIi001-A and MUNIi003-A)","volume":"40","author":"Jelinkova","year":"2019","journal-title":"Stem Cel Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1126\/science.aab1452","article-title":"A Cas9-Guide RNA Complex Preorganized for Target DNA Recognition","volume":"348","author":"Jiang","year":"2015","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1038\/mtna.2015.39","article-title":"Evaluation of 2'-Deoxy-2'-Fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy","volume":"4","author":"Jirka","year":"2015","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0135189","DOI":"10.1371\/journal.pone.0135189","article-title":"DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations","volume":"10","author":"Juan-Mateu","year":"2015","journal-title":"PLoS ONE"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41439-019-0070-x","article-title":"Breakpoint junction Features of Seven DMD Deletion Mutations","volume":"6","author":"Keegan","year":"2019","journal-title":"Hum. Genome"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/965631","article-title":"Understanding the Process of Fibrosis in Duchenne Muscular Dystrophy","volume":"2014","author":"Kharraz","year":"20142014","journal-title":"Biomed. Res. Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/humu.21471","article-title":"Pure Intronic Rearrangements Leading to Aberrant Pseudoexon Inclusion in Dystrophinopathy: A New Class of Mutations?","volume":"32","author":"Khelifi","year":"2011","journal-title":"Hum. Mutat."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-49624-w","article-title":"Production of Adeno-Associated Virus Vectors for In Vitro and In Vivo Applications","volume":"9","author":"Kimura","year":"2019","journal-title":"Sci. Rep."},{"key":"B86","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jacbts.2019.06.006","article-title":"Gene Therapy Rescues Cardiac Dysfunction in Duchenne Muscular Dystrophy Mice by Elevating Cardiomyocyte Deoxy-Adenosine Triphosphate","volume":"4","author":"Kolwicz","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12881-019-0873-0","article-title":"Genetic Analysis of 1051 Chinese Families with Duchenne\/Becker Muscular Dystrophy","volume":"20","author":"Kong","year":"2019","journal-title":"BMC Med. Genet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.ymthe.2018.03.018","article-title":"Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9","volume":"26","author":"Koo","year":"2018","journal-title":"Mol. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0232654","DOI":"10.1371\/journal.pone.0232654","article-title":"Comprehensive Genetic Analysis of 961 Unrelated Duchenne Muscular Dystrophy Patients: Focus on Diagnosis, Prevention and Therapeutic Possibilities","volume":"15","author":"Kumar","year":"2020","journal-title":"PLoS ONE"},{"key":"B88","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.omtn.2017.02.004","article-title":"Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR\/Cas9 System","volume":"7","author":"Lattanzi","year":"2017","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0197084","DOI":"10.1371\/journal.pone.0197084","article-title":"Antisense PMO Cocktails Effectively Skip Dystrophin Exons 45-55 in Myotubes Transdifferentiated from DMD Patient Fibroblasts","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS ONE"},{"key":"B45","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle Delivery of Cas9 Ribonucleoprotein and Donor DNA In Vivo Induces Homology-Directed DNA Repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"B46","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3988\/jcn.2015.11.3.248","article-title":"Clinical and Genetic Characterization of Female Dystrophinopathy","volume":"11","author":"Lee","year":"2015","journal-title":"J. Clin. Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"120709","DOI":"10.1016\/j.ijpharm.2021.120709","article-title":"Saponin Surfactants Used in Drug Delivery Systems: A New Application for Natural Medicine Components","volume":"603","author":"Liao","year":"2021","journal-title":"Int. J. Pharmaceutics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the Treatment of Duchenne Muscular Dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Dddt"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","article-title":"Muscle and Cardiac Therapeutic Strategies for Duchenne Muscular Dystrophy: Past, Present, and Future","volume":"72","author":"\u0141oboda","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children with Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ymthe.2020.05.024","article-title":"Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing","volume":"28","author":"Min","year":"2020","journal-title":"Mol. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.gendis.2019.12.007","article-title":"Promising Therapeutic Approaches Using CRISPR\/Cas9 Genome Editing Technology in the Treatment of Duchenne Muscular Dystrophy","volume":"8","author":"Mollanoori","year":"2021","journal-title":"Genes Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"E6780","DOI":"10.1073\/pnas.1512968112","article-title":"Glucocorticoids Enhance Muscle Endurance and Ameliorate Duchenne Muscular Dystrophy through a Defined Metabolic Program","volume":"112","author":"Morrison-Nozik","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1089\/hum.2019.173","article-title":"Transduction Efficiency of Adeno-Associated Virus Serotypes after Local Injection in Mouse and Human Skeletal Muscle","volume":"31","author":"Muraine","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon Skipping: a First in Class Strategy for Duchenne Muscular Dystrophy","volume":"17","author":"Niks","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","article-title":"Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA","volume":"156","author":"Nishimasu","year":"2014","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.addr.2020.11.002","article-title":"Delivery Technologies for In Utero Gene Therapy","volume":"169","author":"Palanki","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1017\/S0033583518000070","article-title":"Key Role of the REC Lobe during CRISPR-Cas9 Activation by 'sensing', 'regulating', and 'locking' the Catalytic HNH Domain","volume":"51","author":"Palermo","year":"2018","journal-title":"Quart. Rev. Biophys."},{"key":"B59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense Oligonucleotides: The Next Frontier for Treatment of Neurological Disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in Oligonucleotide Drug Delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B82","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene Transfer into Humans--Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1542\/peds.2018-0333H","article-title":"Respiratory Management of the Patient with Duchenne Muscular Dystrophy","volume":"142","author":"Sheehan","year":"2018","journal-title":"Pediatrics"},{"key":"B62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12015-017-9792-7","article-title":"Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy","volume":"14","author":"Siemionow","year":"2018","journal-title":"Stem Cel Rev Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.omtm.2021.03.014","article-title":"Pre-clinical Dose-Escalation Studies Establish a Therapeutic Range for U7snRNA-Mediated DMD Exon 2 Skipping","volume":"21","author":"Simmons","year":"2021","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature15544","article-title":"Conformational Control of DNA Target Cleavage by CRISPR-Cas9","volume":"527","author":"Sternberg","year":"2015","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First Global Approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.nmd.2014.07.003","article-title":"When a Mid-intronic Variation of DMD Gene Creates an ESE Site","volume":"24","author":"Trabelsi","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A High-Fidelity Cas9 Mutant Delivered as a Ribonucleoprotein Complex Enables Efficient Gene Editing in Human Hematopoietic Stem and Progenitor Cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1089\/nat.2018.0759","article-title":"Nonclinical Exon Skipping Studies with 2\u2032-O-Methyl Phosphorothioate Antisense Oligonucleotides in Mdx and Mdx-Utrn\u2212\/\u2212 Mice Inspired by Clinical Trial Results","volume":"29","author":"Van Putten","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.omtn.2019.04.023","article-title":"Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in Mdx Mice","volume":"16","author":"Wang","year":"2019","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B71","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.omtn.2018.02.004","article-title":"Saponins as Natural Adjuvant for Antisense Morpholino Oligonucleotides Delivery In Vitro and in Mdx Mice","volume":"11","author":"Wang","year":"","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.2147\/DDDT.S179008","article-title":"Saponins Enhance Exon Skipping of 2\u2032-O-Methyl Phosphorothioate Oligonucleotide In Vitro and In Vivo","volume":"12","author":"Wang","year":"","journal-title":"Dddt"},{"key":"B73","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-1-4939-9065-8_18","article-title":"Systemic Delivery of Adeno-Associated Viral Vectors in Mice and Dogs","volume":"1937","author":"Wasala","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41591-019-0473-8","article-title":"Principles of and Strategies for Germline Gene Therapy","volume":"25","author":"Wolf","year":"2019","journal-title":"Nat. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2019.01.005","article-title":"rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging Mdx Mouse Heart","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e61584","DOI":"10.1371\/journal.pone.0061584","article-title":"Effective Exon Skipping and Dystrophin Restoration by 2\u2032-O-Methoxyethyl Antisense Oligonucleotide in Dystrophin-Deficient Mice","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS ONE"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.9875","article-title":"Recent Advances of Glucocorticoids in the Treatment of Duchenne Muscular Dystrophy (Review)","volume":"21","author":"Zhang","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target Effects in CRISPR\/Cas9-mediated Genome Engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B79","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1089\/hum.2011.131","article-title":"Novel Mini-Dystrophin Gene Dual Adeno-Associated Virus Vectors Restore Neuronal Nitric Oxide Synthase Expression at the Sarcolemma","volume":"23","author":"Zhang","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.3892\/mmr.2019.9982","article-title":"Clinical and Genetic Characteristics of Female Dystrophinopathy Carriers","volume":"19","author":"Zhong","year":"2019","journal-title":"Mol. Med. Rep."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2022.833833\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T17:38:42Z","timestamp":1655487522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2022.833833\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":89,"alternative-id":["10.3389\/fbioe.2022.833833"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2022.833833","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"article-number":"833833"}}